The MASCC (Multinational Association for Supportive Care in Cancer) Risk Index is a scoring system to identify patients with febrile neutropenia, thus determining the appropriate antibiotic regimes. Low risk groups have MASCC score ≥21, while high risk groups have MASCC score 48 HOURS, neutrophil count >0.5x109/L for two consecutive days, no identified infection, then the patients is advised to discontinue antibiotics. If found to be febrile, the patient is admitted for further investigations and antimicrobial treatment.
For high risk patients, if renal function is normal, the initial empiric antibiotic regimen are given intravenously, with these 3 alternatives: piperacillin-tazobactam (4.5mg Q6H), Imipenem (500mg Q6H), cefepime (2g Q8H).
